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Abstract
Reliable quantification of the macromolecule signals in short echo-time 1H MRS spectra is
particularly important at high magnetic fields for an accurate quantification of metabolite
concentrations (the neurochemical profile) due to effectively increased spectral resolution of
the macromolecule components. The purpose of the present study was to assess two
approaches of quantification, which take the contribution of macromolecules into account in
the quantification step. 1H spectra were acquired on a 14.1 T/26 cm horizontal scanner on five
rats using the ultra-short echo-time SPECIAL (spin echo full intensity acquired localization)
spectroscopy sequence. Metabolite concentrations were estimated using LCModel, combined
with a simulated basis set of metabolites using published spectral parameters and either the
spectrum of macromolecules measured in vivo, using an inversion recovery technique, or
baseline simulated by the built-in spline function. The fitted spline function resulted in a
smooth approximation of the in vivo macromolecules, but in accordance with previous studies
using Subtract-QUEST could not reproduce completely all features of the in vivo spectrum of
macromolecules at 14.1 T. As a consequence, the measured macromolecular ‘baseline’ led to a
more accurate and reliable quantification at higher field strengths.
Keywords: in vivo short echo-time 1H MRS, quantification of neurochemical profile,
macromolecule contribution.
(Some figures in this article are in colour only in the electronic version)
1. Introduction
Localized proton magnetic resonance spectroscopy (1H
MRS) became an important tool for investigating brain
metabolism non-invasively. In animal models, 1H
MRS allows the detection of almost 20 metabolites [1],
also called the neurochemical profile: taurine (Tau),
creatine (Cr), phosphocreatine (PCr), phosphocholine (PCho),
glycerophosphocholine (GPC), glutamate (Glu), glutamine
(Gln), myo-inositol (Ins), ascorbate (Asc), alanine (Ala),
aspartate (Asp), γ -aminobutyrate (GABA), glutathione
(GSH), N-acetylaspartate (NAA), N-acetylaspartylglutamate
(NAAG), glucose (Glc), lactate (Lac), phosphoethanolamine
(PE) and glycine (Gly). Since brain metabolite concentrations
can vary depending on the type of pathology, the usefulness
of 1H MRS has been demonstrated in many brain disorders,
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e.g., in hepatic encephalopathy; Alzheimer’s, Huntington’s
and Parkinson’s diseases; acute traumatic brain injury;
cancer; dementia; etc [2, 3]. The metabolite changes help
to understand metabolic processes related to the studied
pathologies and/or enable to monitor the effect of treatment.
At longer echo times (TE above 20 ms), the number
of spectral lines, which can be used for quantification, is
reduced. As a result, in most in vivo 1H MRS studies
only changes of NAA, Cr+PCr, Cho and Lac have been
detected. Short echo-time in vivo 1H MRS spectra (TE =
1–20 ms) contain more information due to minimal distortions
of multiplets of coupled spin systems such as Glu, Gln, Ins,
Glc, Asp, Ala, GABA, Asc, PE, Gly and Tau. However, due to
overlap of proton signals from brain metabolites, sophisticated
approaches for the separation of the metabolite signals are
required. Consequently, metabolite concentrations are usually
determined by fitting the measured in vivo 1H MRS spectrum
to a linear combination of the spectra of individual metabolites
(also called the metabolite basis set). The metabolite basis set
can be obtained either by measuring aqueous solutions
of pure metabolites or by quantum-mechanical simulations
using known spectral parameters [4]. Well-known time-
and frequency-domain algorithms [5–8], based on metabolite
basis sets, are currently used for an accurate quantification.
The most frequently used algorithms for proton spectra
quantification are QUEST [7] from jMRUI software working
in the time domain and LCModel [5, 6] working in the
frequency domain.
In addition, the spectra measured at short echo times
are further complicated by the presence of macromolecules
(broad signals ascribed mainly to cytosolic proteins [9]), which
further complicates the quantification. Reliable quantification
of the macromolecule signals in short echo-time proton MRS
spectra plays a key role in determining the neurochemical
profile [10, 11]. Consequently, an error in the macromolecule
estimation can lead to substantial errors in the obtained
metabolite concentrations [10, 11]. In addition, it is well
known that changes in the macromolecule concentrations can
be considered as disease markers [12, 13].
Modelling the macromolecule contributions in an in vivo
spectrum can be done using two main approaches. The
macromolecule signal is approximated by a mathematical
function and then included in the fit [5, 6, 13–16] or is
separately estimated in a pre-processing step [7, 8, 14, 18–
22]. It is well known that these procedures provide only a
mathematical approximation of the real in vivo macromolecule
spectra [11, 23]. This mathematical approach can be
satisfactory at low magnetic fields. However, more prior
knowledge is needed to obtain an accurate estimation of the
metabolite concentrations at higher magnetic fields, where the
macromolecule spectrum is better resolved.
In addition to the mathematical approximation of the
macromolecules, a second approach was proposed, which
provides the necessary prior knowledge. It is based on a
separate acquisition of the in vivo macromolecule spectra using
an inversion recovery method (a metabolite-nulled spectrum).
Then, during the quantification step the in vivo acquired
spectrum of macromolecules is either added to the basis set
[10, 11, 24–29] or subtracted from the in vivo signal
[23, 30, 31]. Small residuals attributed to metabolites are still
observed in the metabolite-nulled spectra due to variability
in longitudinal relaxation times of metabolites (T1). Thus,
knowledge of the T1 relaxation times of metabolites is required
for identification of these residual metabolite signals and
subsequent removal by postprocessing.
The purpose of the present study was to assess the
importance of the accurate estimation of the macromolecule
contributions in short echo-time proton MRS spectra.
Consequently, using LCModel [5, 6] we compared
two different approaches of estimating macromolecule
contributions in the quantification step at 14.1 T. In the first
approach, the spectrum of macromolecules was measured
in vivo using the inversion recovery technique and added
to the metabolite basis set. In the second approach, the
macromolecule spectrum was mathematically approximated
using the built-in LCModel spline baseline. Preliminary
results of this study have been reported in [32].
2. Methods
2.1. Animals
In vivo experiments were performed on adult female Sprague-
Dawley rats (five animals, ∼250 g), which were anesthetized
during the experiments with 1.5–2.5% isoflurane using a nose
mask. Body temperature was maintained at 37.5 ± 1.0 ◦C
by circulating warm water around the animals. All animal
experiments were conducted according to federal and local
ethical guidelines and the protocols were approved by the
local regulatory body.
2.2. MRS measurments
Proton spectra were acquired using a Varian Inova (Palo
Alto, CA, USA) console interfaced to a 14.1 T magnet
(Magnex Scientific, Oxford, UK) with a 26 cm horizontal
bore. The magnet was equipped with 12 cm inner-diameter
actively shielded gradient sets giving a maximum gradient of
400 mT m −1 in 120 μs. Home-built 14 mm diameter 1H
quadrature surface coils were used as transceivers. Eddy
currents were minimized using time-dependent quantitative
eddy current field mapping [33]. The static field homogeneity
was adjusted by means of first- and second-order shims using
an EPI version of FASTMAP [34]. Localized images were
obtained in the coronal planes using a multislice fast spin echo
protocol with TE/TR = 60/5000 ms, a slice thickness of 1 mm
and an in-plane resolution of 94 μm. Spectra were acquired
using an ultra-short echo-time spin echo full intensity acquired
localization (SPECIAL) technique (TE/TR = 2.8/4000 ms,
4096 complex data points, SW = 7 kHz, 320 averages)
[1, 35]. The size of the voxel for 1H MRS was 3 × 4 × 4 mm3
including frontal cortex, corpus callosum and striatum. After
first- and second-order shimming, the typical linewidth of the
water resonance at TE = 2.8 ms was 18–20 Hz. The water
signal was suppressed by a series of seven 25 ms asymmetric
variable power RF pulses with optimized relaxation delays
(VAPOR) [36]. The water suppression pulses were interleaved
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with three modules of outer volume saturation as described
elsewhere [36]. To compensate for the magnetic field drift,
spectra were collected in blocks of 16 averages, which were
stored separately in the memory and were corrected for the
relative shift in frequency.
For measuring the in vivo spectrum of macromolecules,
the SPECIAL sequence was extended with a 2 ms nonselective
hyperbolic secant inversion pulse (a bandwidth of 10 kHz),
which was applied at a certain time period (inversion time,
TI) before starting the localization part of the sequence, as
described in [1]. A series of these inversion recovery spectra
(TE of 2.8 ms or 40 ms, TR of 2500 ms and 640 averages)
were measured with inversion times of 420, 600, 750, 850 and
1000 ms. Residual signals attributed to incompletely nulled
metabolites were removed using HLSVD (Hankel-Lanczos
singular value decomposition algorithm) [37] from the jMrui
software [38].
2.3. Data analysis
Metabolite concentrations were estimated using the LCModel,
combined with a simulated basis set of metabolites and
either the spectrum of macromolecules measured in vivo
using an inversion recovery technique or the spectrum of
macromolecules mathematically approximated using the built-
in LCModel spline baseline. The water signal was used as an
internal reference and the average relative differences between
the concentration estimates using the two approaches were
compared. The basis set was created by quantum mechanics
simulations, based on the density-matrix formalism [39], using
published values of J-coupling constants and chemical shifts
[4]. The Crame´r–Rao lower bounds (CRBs) were calculated
by LCModel as a measure of the reliability of the metabolite
estimates. The metabolite concentrations were estimated for
the following 19 neurochemical profiles: Ala, Asp, PCho, Cr,
PCr, GABA, Gln, Glu, GSH, Gly, Ins, Lac, NAA, Tau, Asc,
Glc, NAAG, GPC and PE.
To evaluate any possible differences between the
metabolite concentrations obtained using the two approaches,
the metabolite concentrations were statistically compared pair-
wise using a paired two-tailed Student’s t-test.
3. Results and discussion
Figure 1 displays the macromolecule spectrum acquired
in vivo in the rat brain at 14.1 T. The main resonances of
the macromolecules were well identified. However, since T1
relaxation times of metabolite resonances are not identical
[40], a macromolecule spectrum with completely suppressed
metabolite resonances could not be obtained. Consequently,
based on the evolution of the metabolite intensities over the
series of inversion recovery spectra (changing from negative
to positive), the spectrum at TI = 750 ms and TE = 2.8 ms
(figure 1(a)) was taken as a basis for the spectrum of
macromolecules, since it contained the smallest residual
metabolite peaks (positive or negative). In addition, the
residual metabolite peaks were confirmed by measuring an
inversion recovery spectrum with the same TI = 750 ms,
(c)
(b)
(a)
Figure 1. Estimation of the spectrum of macromolecules based on
IR-SPECIAL spectra using the TI = 750 ms and TE = 2.8 ms. The
spectrum (a) showing minimal residual peaks (negative peaks of
NAA at 2 ppm and Tau at 3.4 ppm, and positive peaks of NAA at
2.7 ppm, GPC/PCho at 3.2, Ins at 3.6 ppm and Cr/PCr at 3.9 ppm)
was taken as a basis for the spectrum of macromolecules. The
spectrum (b) presents the final macromolecule spectrum measured
with TI = 750 ms and TE = 40 ms. The spectrum (c) displays the
final macromolecule spectrum after removal of the residual
metabolite peaks using HLSVD. The residual signal of NAA at
2.7 ppm marked with an asterisk in the spectrum (b) is reduced and
inverted relative to the spectrum from (a) due to J-evolution.
however, with a longer TE = 40 ms. In this spectrum
(figure 1(b)) the residual signals of metabolites were visible
due to longer T2 relaxation times, while the signals of
macromolecules were substantially reduced due to their short
T2 relaxation times. The residual peaks of NAA at 2.0 and
2.7 ppm, Tau at 3.4 ppm, total choline at 3.2 ppm, Ins at
3.6 ppm and total Cr at 3.9 ppm, identified in the spectrum
in figure 1(b), were then removed from the macromolecule
spectrum in figure 1(a) using the HLSVD algorithm. Since
the residual peaks were visible in the in vivo spectrum
(figure 1(a)), they were removed by using the option
from the HLSVD algorithm, in which the user defines the
frequency region to be removed in the spectrum. The final
macromolecule spectrum is displayed in figure 1(c).
The LCModel analysis of a representative 14.1 T spectrum
is shown in figure 2. Figure 2(a) presents the measured
in vivo spectrum in the rat brain at 14.1 T. As can
be seen, despite excellent spectral dispersion at 14.1 T,
many spectral lines of metabolites remained overlapped
among each other as well as with macromolecule signals.
Figures 2(b) and (c) display the corresponding LCModel fits
using the measured macromolecule spectrum (figure 2(b))
and the built-in LCModel spline baseline (figure 2(c)). The
LCModel quantification using a basis set of simulated spectra
of metabolites combined with the measured spectrum of the
macromolecules provided an excellent fit to the experimental
data. The spectrum fitted without the experimental
macromolecule spectrum provided a poor match of the
experimental spectrum, with residuals observed particularly
in the spectral region from 0.5 to 2.0 ppm, compared to the
LCModel fit with the macromolecule spectrum. The fits of the
individual metabolites are plotted in figure 2(d).
Figure 3(a) shows the built-in LCModel spline baselines
obtained from five rats and overlaid in different colours on a
representative 14.1 T in vivo spectrum of rat brain, whereas
figure 3(b) displays the in vivo measured macromolecule
3
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Figure 2. The LCModel analysis of a representative 14.1 T spectrum. The measured in vivo spectrum in the rat brain at 14.1 T is shown in
(a). The corresponding LCModel fits using the measured macromolecule spectrum and the built-in LCModel spline baseline are also
displayed in (b) and (c), respectively. The traces below represent from top to bottom, measured (b) or modelled (c) macromolecules,
residual baseline and the difference between the measured and fitted data (also called residue of the quantification). The fits of the individual
metabolites are plotted in (d).
spectrum combined with the same 14.1 T in vivo spectrum of
the rat brain. The built-in LCModel spline baselines obtained
from five rats fitted well the signals of macromolecules and
they were highly consistent among the animals, except for the
region close to H2O at around 4.5 ppm (figure 3(a)). However,
this smooth approximation of the in vivo macromolecules
could not reproduce completely all features of the in vivo
spectrum of macromolecules at 14.1 T as shown in figure 3(b).
As can be seen in figure 3(a), compared to the in vivo measured
spectrum of macromolecules, the built-in LCModel spline
baseline was raised around 2.0 and 4.0 ppm and lowered
around 3.0 and 3.2 ppm, leading to a decrease and an increase
of concentrations of metabolites resonating in these regions,
respectively.
The mean values and standard deviations of the metabolite
concentrations obtained using the two approaches are shown in
figure 4. Although there was an overall reasonable agreement
in metabolite concentrations, NAA and Glu concentrations
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Figure 3. A representative 14.1 T spectrum (320 averages) of rat brain measured from a VOI = 3 × 4 × 4 mm3 (blue line) combined with
(a) the built-in LCModel spline baselines obtained from fitting spectra of five rats, which are plotted in different colours and with (b) the
measured in vivo macromolecule spectrum (green line). Note the difference in the macromolecules estimation around 2 ppm, 3.0 ppm,
3.2 ppm and 4 ppm. Reproduced with permission from [32] Copyright © 2008 IEEE.
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Figure 4. The mean values and standard deviations of the metabolite concentrations obtained using: (1) the spectrum of macromolecules
measured in vivo (black bars) and (2) the built-in LCModel spline baseline (light blue bars). Reproduced with permission from [32]
Copyright © 2008 IEEE.
were slightly lower (8–15%) and Cr+PCr, GPC+PCho and
Gly concentrations were slightly higher (10–17%) when using
the fitted splines. A systematic increase of Glc, GABA,
PCho, GSH, PE and Asp concentrations (∼30–70%) and a
decrease of Ala, Asc, NAAG and Lac concentrations (∼70–
100%) were noted when using the fitted splines compared with
the approach using measured macromolecules. For almost
all metabolites, the standard deviations and CRBs of the
metabolite concentrations were similar in the two approaches,
except for a few low concentrated metabolites (Ala, Lac, Asc
and NAAG), which were higher for the baseline fitted with
splines. Statistical significant differences with p values in
the range from 0.02 to 0.0001 were obtained for Ala, Asp,
GABA, GSH, Lac, NAA, NAAG, Asc, Glc and PE. The
metabolite concentrations obtained using the in vivo measured
macromolecule spectrum, were in agreement with previous
studies [1, 10, 28]. Figure 3 demonstrates that the bias in
the metabolite concentrations is due to the raised or lowered
baseline fitted with the spline functions.
Only two studies at lower magnetic fields of 3 T and 7 T
[11, 23] compared the simulated and experimentally obtained
spectra of macromolecules in the quantification of in vivo
proton spectra using the Subtract-QUEST algorithm [7]. In
this algorithm, the macromolecule spectrum is mathematically
estimated from the first data points of the MRS signal. This
approach exploits the fact that the macromolecule signals
decay rapidly in the time domain due to shorter T2 relaxation
times. Significant differences in the determined concentrations
were obtained by the authors when using the mathematical
estimation of the macromolecules. These differences are in
agreement with our study. Moreover, the authors also observed
that the macromolecule spectrum estimated by Subtract-
QUEST displayed only broader features, which disagrees with
what is actually seen in the measured spectra.
Our results showed that an experimental estimation of
the macromolecule spectrum can improve the quality of the
fit at 14.1 T. The absence of the measured macromolecule
spectrum in the database led to a large and unpredictable
bias in the concentrations of many metabolites. Even at
the highest magnetic fields available for in vivo experiments,
spectral overlap of proton signals from brain metabolites
and macromolecules still requires an experimental assessment
of macromolecular contribution to the proton spectrum for
an accurate metabolite quantification. The main reason
for the poor mathematical estimation of macromolecules
at high magnetic fields is due to the fact that the largely
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field-independent linewidth of the signals of macromolecules
increasingly approaches that of metabolites. As can also be
seen from [1, 10, 11, 41], an effectively increased spectral
resolution of the macromolecule components can be observed
at higher magnetic field strengths, making the estimation of the
macromolecules by means of mathematical approximations
even more difficult.
4. Conclusion
To our knowledge, this is the first study demonstrating the
importance of the accurate assessment of the macromolecule
contributions in quantification of short echo-time proton MR
spectra using LCModel. Even if the fitted splines reproduce
the in vivo macromolecules very well, we can conclude that
the measured macromolecular ‘baseline’ represents additional
prior knowledge, which leads to a more accurate and reliable
quantification. This kind of knowledge becomes important
particularly at higher static magnetic fields.
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